Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 34
1946 103
1947 123
1948 133
1949 198
1950 360
1951 464
1952 473
1953 600
1954 541
1955 498
1956 532
1957 581
1958 550
1959 536
1960 450
1961 507
1962 736
1963 1419
1964 2120
1965 1594
1966 1806
1967 2211
1968 2580
1969 3013
1970 2840
1971 3257
1972 3331
1973 3483
1974 3760
1975 3468
1976 3302
1977 3327
1978 3259
1979 3404
1980 3474
1981 3599
1982 3651
1983 3870
1984 4269
1985 4493
1986 4457
1987 4267
1988 4517
1989 4714
1990 4833
1991 4982
1992 5210
1993 5621
1994 6091
1995 6471
1996 6512
1997 6990
1998 7230
1999 7307
2000 7458
2001 7464
2002 7343
2003 7413
2004 7293
2005 7733
2006 7937
2007 7817
2008 7835
2009 7632
2010 7660
2011 7694
2012 7868
2013 7803
2014 7528
2015 7221
2016 7127
2017 6854
2018 6550
2019 6511
2020 6288
2021 5575
2022 5176
2023 4333
2024 4885
2025 4975
2026 1447

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319,228 results

Results by year

Filters applied: . Clear all
The following terms were not found in PubMed: activity+Carrageenan+Cassia, sophera+Histamine
Page 1
Leukotriene-receptor antagonists.
Lipworth BJ. Lipworth BJ. Lancet. 1999 Jan 2;353(9146):57-62. doi: 10.1016/S0140-6736(98)09019-9. Lancet. 1999. PMID: 10023966 Review.
The published data with leukotriene-receptor antagonists such as montelukast or zafirlukast show good antiasthmatic activity over a wide spectrum of asthma severity either as monotherapy or with inhaled steroids. ...Here I overview the clinical pharmacology of leukotriene …
The published data with leukotriene-receptor antagonists such as montelukast or zafirlukast show good antiasthmatic activity over a w …
Disease-modifying anti-asthmatic drugs.
Lommatzsch M, Brusselle GG, Canonica GW, Jackson DJ, Nair P, Buhl R, Virchow JC. Lommatzsch M, et al. Lancet. 2022 Apr 23;399(10335):1664-1668. doi: 10.1016/S0140-6736(22)00331-2. Lancet. 2022. PMID: 35461560 Review. No abstract available.
[Modern asthma management].
Lommatzsch M. Lommatzsch M. Dtsch Med Wochenschr. 2024 Jul;149(13):764-770. doi: 10.1055/a-2161-1802. Epub 2024 Jun 11. Dtsch Med Wochenschr. 2024. PMID: 38863145 Review. German.
Basic measures, treatment with DMAADs ("disease-modifying anti-asthmatic drugs": predominantly inhaled corticosteroids, biologics, and allergen immunotherapy) and treatment of comorbidities are the cornerstones of modern asthma management. ...
Basic measures, treatment with DMAADs ("disease-modifying anti-asthmatic drugs": predominantly inhaled corticosteroids, biolog …
Remission in asthma.
Lommatzsch M. Lommatzsch M. Curr Opin Pulm Med. 2024 May 1;30(3):325-329. doi: 10.1097/MCP.0000000000001068. Epub 2024 Mar 5. Curr Opin Pulm Med. 2024. PMID: 38441430 Free PMC article. Review.
With the advent of highly effective, anti-inflammatory disease-modifying antiasthmatic drugs (DMAADs), treatment goals of asthma have changed. Several national guidelines have now announced remission as a general treatment goal in asthma. ...
With the advent of highly effective, anti-inflammatory disease-modifying antiasthmatic drugs (DMAADs), treatment goals of asthma have …
Letter from Spain.
Rázquin Arias M, Ventura Wichner PS, López-Escobar A, Díaz-Conradi A, Daoud Pérez Z. Rázquin Arias M, et al. Respirology. 2021 Dec;26(12):1190-1191. doi: 10.1111/resp.14178. Epub 2021 Nov 2. Respirology. 2021. PMID: 34725891 Free article. No abstract available.
Identification of cough-variant asthma phenotypes based on clinical and pathophysiologic data.
Zhan W, Wu F, Zhang Y, Lin L, Li W, Luo W, Yi F, Dai Y, Li S, Lin J, Yuan Y, Qiu C, Jiang Y, Zhao L, Chen M, Qiu Z, Chen R, Xie J, Guo C, Jiang M, Yang X, Shi G, Sun D, Chen R, Zhong N, Shen H, Lai K. Zhan W, et al. J Allergy Clin Immunol. 2023 Sep;152(3):622-632. doi: 10.1016/j.jaci.2023.04.017. Epub 2023 May 11. J Allergy Clin Immunol. 2023. PMID: 37178731
BACKGROUND: Cough-variant asthma (CVA) may respond differently to antiasthmatic treatment. There are limited data on the heterogeneity of CVA. OBJECTIVE: We aimed to classify patients with CVA using cluster analysis based on clinicophysiologic parameters and to unveil the …
BACKGROUND: Cough-variant asthma (CVA) may respond differently to antiasthmatic treatment. There are limited data on the heterogeneit …
Treatable Traits as a Pathway to Remission in Asthma.
Farinha I, Gibson PG, McDonald VM, Heaney LG. Farinha I, et al. J Allergy Clin Immunol Pract. 2025 Jul;13(7):1542-1552. doi: 10.1016/j.jaip.2025.05.002. Epub 2025 May 8. J Allergy Clin Immunol Pract. 2025. PMID: 40348084 Free article. Review.
In recent years, the significant impact of disease-modifying anti-asthmatic drugs has provided a chance to reevaluate goals in asthma treatment and consider remission as a more ambitious and achievable target. ...
In recent years, the significant impact of disease-modifying anti-asthmatic drugs has provided a chance to reevaluate goals in …
Anaphylaxis due to antiallergic and antiasthmatic biologics.
Furci F, Luxi N, Senna G, Trifirò G. Furci F, et al. Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):364-369. doi: 10.1097/ACI.0000000000000937. Epub 2023 Jul 25. Curr Opin Allergy Clin Immunol. 2023. PMID: 37555938 Review.
PURPOSE OF REVIEW: To provide a better understanding of the risk of anaphylaxis due to antiallergic and antiasthmatic biologics through an analysis of data reported in literature and in clinical trials, and by conducting a retrospective descriptive analysis of individual c …
PURPOSE OF REVIEW: To provide a better understanding of the risk of anaphylaxis due to antiallergic and antiasthmatic biologics throu …
Synthesis, antiasthmatic, and insecticidal/antifungal activities of allosamidins.
Huang G, Huang H. Huang G, et al. J Enzyme Inhib Med Chem. 2019 Dec;34(1):1226-1232. doi: 10.1080/14756366.2019.1623208. J Enzyme Inhib Med Chem. 2019. PMID: 31307248 Free PMC article. Review.
Allosamidins are chitinase inhibitors that can be used to study the physiological effects of chitinases in a variety of organisms. They have the novel antiasthmatic activity and insecticidal/antifungal activities. Herein, the synthesis and activities of allosamidins were s …
Allosamidins are chitinase inhibitors that can be used to study the physiological effects of chitinases in a variety of organisms. They have …
319,228 results
You have reached the last available page of results. Please see the User Guide for more information.